DeFi expert Jim Bianco joins Jared Blikre to break down an interesting year ahead on Wednesday, 1/12 at 2PM ET.
Two leading health brands have come together with an all-in-one way to monitor your nutrition and wellness
SAN FRANCISCO, Jan. 11, 2022 /PRNewswire/ — Today RENPHO, a global leader in designing smart products for healthy living, announced an integration with MyFitnessPal, the #1 global nutrition and food tracking app, to bring users an improved and connected wellness tracking experience.
RENPHO and MyFitnessPal share a mission to help people reach their health goals through personalized data-led insights and guidance. MyFitnessPal has helped 200 million members easily log or scan what they're eating with one of the largest food databases in the world. Paired with the depth of RENPHO's biometrics monitoring, the integration will offer an innovative wellness solution this New Year.
"We are thrilled to bring our customers even more ways to track their health and wellness goals through our integration with MyFitnessPal," said Tiffany Ou, Chief Marketing Officer of RENPHO. "The combined insights from MyFitnessPal's food and nutrition tracking and our biometrics with smart fitness products create a truly customized, holistic view of health for consumers."
The integration will allow members to accurately track their health metrics and identify nutrition, diet and exercise trends by:
Syncing their MyFitnessPal accounts with RENPHO products, including the brand's Smart Food Scale, Smart Body Scale, AI Smart Bike and more, customizing health data to their personal profiles in real time
Utilizing MyFitnessPal's comprehensive features, such as nutrition and macro tracking, barcode scan, guided plans, recipes and workout routines
This integration furthers MyFitnessPal's goal to make nutrition tracking easy and seamless and help members on their overall health journey.
"At MyFitnessPal, we believe that the more you know about your health and nutrition, the faster you'll reach your wellness goals," said Mark Merolli, Head of Corporate and Business Development. "We know that a lot of our members use RENPHO devices, and we're delighted to offer an easy, connected experience for them."
About RENPHO
Founded in 2015, RENPHO was born with the vision to empower people worldwide to improve all aspects of their life by granting a passport to their own health data. Its mission is to create a growing ecosystem of smart lifestyle products that provide advanced solutions which are essential, accessible and everyday. Widely recognized for its smart weight scales and massage products, RENPHO continues to be a leading innovator in health & wellness technology, developing products that are carefully researched to enhance people's health, fitness and wellness journey. To learn more, visit RENPHO.com or follow RENPHO on Instagram, Twitter, Facebook, TikTok and LinkedIn.
About MyFitnessPal
MyFitnessPal is the #1 global nutrition and food tracking app for achieving health goals. Since 2005, MyFitnessPal has empowered over 200 million users in over 120 countries to log food intake, record exercise activity and weight, track wellness habits, and achieve their health and fitness goals. As one of the world's most trusted and leading resources on nutrition, MyFitnessPal's mission is to ignite powerful nutrition and wellness change in members by empowering them to succeed on their own terms through personalized data-led insights, guidance, and unwavering support. With one of the largest food databases in the world comprising over 14 million foods, access to over 500 recipes, over 150 workout routines, 200 exercise demos and over 35 connected fitness partners, MyFitnessPal provides users with tools for positive healthy change. The MyFitnessPal app is available on the App Store and Google Play store. To learn more, visit myfitnesspal.com or follow MyFitnessPal on Instagram, Twitter, Facebook and LinkedIn.
View original content to download multimedia:https://www.prnewswire.com/news-releases/renpho-and-myfitnesspal-introduce-the-ultimate-tracking-solution-for-your-wellness-resolutions-301458495.html
SOURCE RENPHO
Novavax CEO Stanley Erck joins Yahoo Finance Live to discuss the 2022 outlook for global COVID-19 vaccine distribution.
Medicare should only cover Biogen ‘s Aduhelm drug for certain recipients who are enrolled in qualifying clinical trials, officials at the organization that oversees the national health insurance program proposed Tuesday evening. If approved, the decision would restrict access to the first Alzheimer’s therapy approved in decades by the Food and Drug Administration. Dr. Lee Fleisher, chief medical officer of the Centers for Medicare and Medicaid Services, said in a news release announcing the draft ruling that even though the drug shows promise, it could also harm patients.
Veru (NASDAQ: VERU), an oncology-focused biotech, saw its share price leap by over 20% on Tuesday, crushing not only the top stock market indexes, but also many peers in its sector. The reason why was clear: The company received an important regulatory nod for one of its key pipeline projects. In a press release published on Monday, Veru announced that the Food and Drug Administration (FDA) has granted Fast Track designation for the phase 3 registration program of its enobosarm.
What happened Shares of Moderna (NASDAQ: MRNA) were sliding 5.1% lower as of 11 a.m. ET on Tuesday. The decline appears to be the result of some profit-taking after Moderna's shares jumped on Monday after the company's CEO, Stéphane Bancel, said during an interview on CNBC that Moderna will soon begin clinical trials for a version of its COVID-19 vaccine that specifically targets the coronavirus omicron variant.
Biogen stock tumbled late Tuesday after U.S. regulators limited which patients can access the controversial Alzheimer's treatment, Aduhelm.
The Centers for Medicare and Medicaid Services said it will cover the cost of the drug Aduhelm, but as part of further clinical testing.
A new real-world study funded by the Department of Veterans Affairs (VA) showed that compared to those who received Pfizer Inc's (NYSE: PFE) COVID-19 vaccine, Moderna Inc (NASDAQ: MRNA) vaccine recipients had a significantly lower risk of SARS-CoV-2 infection and related hospitalizations. Lower risk was observed across all age groups, comorbidity-burden categories, and race. Authors of the study, published as a pre-print last week, noted differences between Moderna's mRNA-1273 vaccine and Pfizer
The U.S. purchased 10 million courses of Pfizer’s antiviral treatment in a $5 billion deal. Where are they?
Ocugen jumped into the race to develop a vaccine for COVID-19 by partnering up with Bharat Biotech, an India-based biotech company. Bharat Biotech ran a late-stage clinical trial for the vaccine in question, Covaxin, in India, and earned emergency use authorization (EUA) for it there.
The spread of the Omicron variant has sent federal authorities scrambling to clarify Covid safety guidance for the purposes of everyday life
Despite having a billion-dollar drug in its portfolio, the potential for backdoor entry into the marijuana market, and being consistently profitable for years, Jazz Pharmaceuticals (NASDAQ: JAZZ) was battered about the head by the stock market last year with its stock falling 22.8%, according to data provided by S&P Global Market Intelligence. The decline started during the summer when Jazz reported second-quarter earnings that showed sales of its top sleep disorder drug, Xylem, plunged 25% from the prior year. While that's because patients were being transitioned over to its next-generation drug, Xywav, combined sales were only 3% higher.
Shark Tank investor Kevin O’Leary may be bulking up his portfolio with cryptocurrency these days, but he is slimming down his weight.
Pfizer is entering the CRISPR space through a $1.35 billion deal with Beam, the companies said Monday. But Beam stock fell in response.
The U.S. Centers for Disease Control and Prevention updated its recommendations that people should isolate for five days after a COVID-19 infection, instead of 10. A spokesperson for CVS said that the company is providing five days of paid leave for eligible full- and part-time workers, except where state or city paid leave laws provide for more. The company also added that paid leave is available only to employees who are vaccinated, approved for a reasonable accommodation, or otherwise covered by local laws.
Companies like Intellia Therapeutics and Editas Medicine are saying that this year will bring exciting developments.
Scientists are seeing signals that COVID-19′s alarming omicron wave may have peaked in Britain and is about to do the same in the U.S., at which point cases may start dropping off dramatically. The reason: The variant has proved so wildly contagious that it may already be running out of people to infect, just a month and a half after it was first detected in South Africa. “It’s going to come down as fast as it went up,” said Ali Mokdad, a professor of health metrics sciences at the University of Washington in Seattle.
Experts warn that America’s Omicron surge is already more severe than in other countries and will only get worse as it spreads from highly vaccinated cities to less protected parts of the U.S.
SOPHiA GENETICS SA (NASDAQ: SOPH), the creator of a global data pooling and knowledge sharing platform that advances data-driven medicine, announced today strong traction in the launch phase of their DEEP-Lung-IV clinical study (NCT04994795). Since officially launching last month, 12 sites across 5 countries have already signed up for participation in the study.
Novartis says it will license antiviral Covid-19 treatment ensovibep from Molecular Partners following positive trial results.
The rollout comes amid long lines at testing sites and President Joe Biden's promise to increase the number of tests available.

source